Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940133596> ?p ?o ?g. }
- W2940133596 endingPage "51" @default.
- W2940133596 startingPage "39" @default.
- W2940133596 abstract "Diabetic dyslipidaemia, characterized by quantitative, qualitative and kinetic changes in all major circulating lipids, contributes to the increased cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). A promising therapeutic avenue is the inhibition of the proprotein convertase subtilisin kexin 9 (PCSK9) with human monoclonal antibodies (mAbs) that potently reduce plasma low‐density lipoprotein cholesterol (LDL‐C) levels on top of statin treatment. The aim of this review is to evaluate the efficacy of PCSK9 inhibitors to lower the residual cardiovascular risk of T2DM patients and to discuss the safety of PCSK9 inhibition in these patients. PCSK9 inhibitors potently lower plasma LDL‐C levels in T2DM patients and reduce risk for the development of cardiovascular disease. Anti‐PCSK9 mAbs are generally not more or less effective in T2DM patients compared to a general high‐risk population. Nevertheless, due to their higher cardiovascular risk, the absolute risk reduction of major cardiovascular events is more significant in T2DM patients. This suggests that treatment of T2DM patients with anti‐PCSK9 mAbs could be attractive from a cost‐effectiveness perspective. Treatment with anti‐PCSK9 mAbs did not result in significant treatment‐emergent adverse effects. While genetic studies suggest a potential link between PCSK9 inhibition and glucose homeostasis, anti‐PCSK9 mAbs did not worsen glycaemic control in T2DM patients, but their safety should be verified after a longer‐term follow‐up." @default.
- W2940133596 created "2019-04-25" @default.
- W2940133596 creator A5009182471 @default.
- W2940133596 creator A5063605678 @default.
- W2940133596 date "2019-04-01" @default.
- W2940133596 modified "2023-09-30" @default.
- W2940133596 title "Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia" @default.
- W2940133596 cites W1520609538 @default.
- W2940133596 cites W1842301723 @default.
- W2940133596 cites W1972021378 @default.
- W2940133596 cites W1981250518 @default.
- W2940133596 cites W1994381425 @default.
- W2940133596 cites W2001328643 @default.
- W2940133596 cites W2001813316 @default.
- W2940133596 cites W2005088441 @default.
- W2940133596 cites W2012848826 @default.
- W2940133596 cites W2019173226 @default.
- W2940133596 cites W2020034972 @default.
- W2940133596 cites W2024100456 @default.
- W2940133596 cites W2032241244 @default.
- W2940133596 cites W2032630767 @default.
- W2940133596 cites W2035816889 @default.
- W2940133596 cites W2040612932 @default.
- W2940133596 cites W2055409036 @default.
- W2940133596 cites W2060132183 @default.
- W2940133596 cites W2067539811 @default.
- W2940133596 cites W2069616685 @default.
- W2940133596 cites W2079979713 @default.
- W2940133596 cites W2082270778 @default.
- W2940133596 cites W2086089950 @default.
- W2940133596 cites W2088358411 @default.
- W2940133596 cites W2093535758 @default.
- W2940133596 cites W2097510503 @default.
- W2940133596 cites W2097870088 @default.
- W2940133596 cites W2099654648 @default.
- W2940133596 cites W2103518970 @default.
- W2940133596 cites W2104005551 @default.
- W2940133596 cites W2106759269 @default.
- W2940133596 cites W2107049546 @default.
- W2940133596 cites W2112345742 @default.
- W2940133596 cites W2116970126 @default.
- W2940133596 cites W2119087485 @default.
- W2940133596 cites W2127791131 @default.
- W2940133596 cites W2133717826 @default.
- W2940133596 cites W2140272923 @default.
- W2940133596 cites W2152113018 @default.
- W2940133596 cites W2154574841 @default.
- W2940133596 cites W2163720603 @default.
- W2940133596 cites W2164089346 @default.
- W2940133596 cites W2164103877 @default.
- W2940133596 cites W2164750952 @default.
- W2940133596 cites W2266600614 @default.
- W2940133596 cites W2481252033 @default.
- W2940133596 cites W2486690983 @default.
- W2940133596 cites W2521340203 @default.
- W2940133596 cites W2522643247 @default.
- W2940133596 cites W2526556731 @default.
- W2940133596 cites W2529053508 @default.
- W2940133596 cites W2552966671 @default.
- W2940133596 cites W2557654447 @default.
- W2940133596 cites W2559592043 @default.
- W2940133596 cites W2560283770 @default.
- W2940133596 cites W2560745954 @default.
- W2940133596 cites W2560899778 @default.
- W2940133596 cites W2563852152 @default.
- W2940133596 cites W2573169027 @default.
- W2940133596 cites W2588974371 @default.
- W2940133596 cites W2595169180 @default.
- W2940133596 cites W2596179513 @default.
- W2940133596 cites W2601739689 @default.
- W2940133596 cites W2604903590 @default.
- W2940133596 cites W2606281213 @default.
- W2940133596 cites W2622782889 @default.
- W2940133596 cites W2731199601 @default.
- W2940133596 cites W2743957775 @default.
- W2940133596 cites W2748800769 @default.
- W2940133596 cites W2754562397 @default.
- W2940133596 cites W2756174617 @default.
- W2940133596 cites W2763903839 @default.
- W2940133596 cites W2780743843 @default.
- W2940133596 cites W2786448024 @default.
- W2940133596 cites W2787959738 @default.
- W2940133596 cites W2789891083 @default.
- W2940133596 cites W2790059086 @default.
- W2940133596 cites W2797253756 @default.
- W2940133596 cites W2800649167 @default.
- W2940133596 cites W2802452781 @default.
- W2940133596 cites W2803715345 @default.
- W2940133596 cites W2803816352 @default.
- W2940133596 cites W2809860024 @default.
- W2940133596 cites W2811289319 @default.
- W2940133596 cites W2883638172 @default.
- W2940133596 cites W2887185538 @default.
- W2940133596 cites W2890723626 @default.
- W2940133596 cites W2899669642 @default.
- W2940133596 cites W2899997727 @default.
- W2940133596 cites W2900040914 @default.
- W2940133596 doi "https://doi.org/10.1111/dom.13636" @default.